Bristol-Myers Squibb stock holds steady as 2025 revenue tops $46.3 billion
Published on 07/17/2026 at 03:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb (US1078421011) is supported by 2025 revenue of $46.3 billion and adjusted EPS of $6.44, with a market capitalization of about $108 billion as of 17 July 2026.
The latest company context also includes 2025 adjusted EPS growth versus 2024, giving the stock a clear earnings base even without a fresh event in the available results.
2025 revenue above $46 billion
For fiscal 2025, Bristol-Myers Squibb reported revenue of $46.3 billion and adjusted EPS of $6.44. The revenue figure provides the main scale reference for the shares, while EPS shows the profit base investors normally use to frame valuation.
That combination matters because revenue and earnings are the two numbers that best connect operating performance to the stock price. The 2025 figures also give a dated comparison point for anyone tracking the company into 2026.
Market value near $108 billion
As of 17 July 2026, Bristol-Myers Squibb had a market capitalization of about $108 billion. That market value is the clearest current market metric available from the research set and gives the stock a large-cap profile.
The earnings base of $6.44 adjusted EPS against a roughly $108 billion equity value implies the market is still pricing the company as a major pharmaceutical name rather than a speculative turnaround story.
Bristol-Myers Squibb fundamentals and filings
Review the company record, reports, and investor material linked to the stock.
Adjusted EPS at $6.44
Adjusted EPS of $6.44 for 2025 is the second core operating number. Compared with the revenue line, it adds a profitability lens and helps explain why the stock can still trade as a large, established health care name.
For readers following Bristol-Myers Squibb stock, the next useful comparison is whether future quarters can expand on that earnings base or merely defend it.
Product risk stays visible
The company profile remains tied to its prescription-drug portfolio, so product concentration and pipeline execution stay central to the equity story. That makes reported revenue and EPS especially important, because they reflect how the current portfolio translates into cash generation.
In practical terms, the stock is still judged more on commercial execution than on narrative. Revenue of $46.3 billion and adjusted EPS of $6.44 are the hard markers that frame that judgment.
Stock level and scale
Bristol-Myers Squibb stock is therefore best read through scale, earnings, and market value rather than short-term headlines. The available research set supports a simple snapshot: $46.3 billion of 2025 revenue, $6.44 of adjusted EPS, and a roughly $108 billion market capitalization as of 17 July 2026.
If a new company release or analyst note appears later, those three figures remain the clean baseline for judging whether the next update adds real momentum or just confirms the current profile.
Company: Bristol-Myers Squibb Company
ISIN: US1078421011
Ticker: NYSE: BMY
Trading venue: NYSE
Market capitalization: about $108 billion (as of 17 July 2026)
Sector / Industry: Health Care / Pharmaceuticals
Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
